Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Losmapimod. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 known ✓ | Q16539 | 16/20 | 1.00 |
| ▸ | MAPK11 known ✓ | Q15759 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 12/20 | 1.00 |
| ▸ | BUB1 | O43683 | 1/20 | 1.00 |
| ▸ | PRKACG | P22612 | 1/20 | 1.00 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 1.00 |
| ▸ | ACSL5 | Q9ULC5 | 1/20 | 1.00 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Losmapimod SCHEMBL29367949 | 1.00 | MAPK14 (1.00) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| Losmapimod SCHEMBL29888732 | 1.00 | MAPK14 (1.00) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL20448678 | 0.93 | MAPK14 (0.86) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL20883154 | 0.92 | MAPK14 (0.85) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL20460539 | 0.92 | MAPK14 (0.84) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL3427536 | 0.91 | MAPK14 (0.84) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL3427034 | 0.91 | MAPK14 (0.83) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL3409067 | 0.90 | MAPK14 (0.82) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL3431414 | 0.89 | MAPK14 (0.82) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL3429819 | 0.89 | MAPK14 (0.80) | MAPK14CYP2C9MAPK11BUB1PRKACG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12145981-B2 | Methods and compounds for the treatment or prevention of severe influenza | Poolbeg Pharma (UK) Limited (GB) | 2024-11-19 | — | — | US | claimed |
| US-20220275062-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | ORPH PHARMA IP COMPANY LIMITED (GB) | 2022-09-01 | — | — | US | claimed |
| US-11339207-B2 | Methods and compounds for the treatment or prevention of severe influenza | ORPH PHARMA IP COMPANY LIMITED (GB) | 2022-05-24 | — | — | US | claimed |
| EP-3478322-B1 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | HVIVO SERVICES LTD (GB) | 2020-12-30 | — | — | EP | claimed |
| US-20200237728-A1 | CHEMOTHERAPEUTIC METHODS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2020-07-30 | — | — | US | claimed |
| EP-3478322-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | hVIVO Services Limited (GB) | 2019-05-08 | — | — | EP | claimed |
| US-20180071376-A1 | TOLEROGENIC NANOPARTICLES FOR TREATING DIABETES MELLITUS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2018-03-15 | — | — | US | claimed |
| EP-3274053-A1 | TOLEROGENIC NANOPARTICLES FOR TREATING DIABETES MELLITUS | The Brigham and Women's Hospital, Inc. (US) | 2018-01-31 | — | — | EP | claimed |
| WO-2018007788-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | HVIVO SERVICES LIMITED (GB) | 2018-01-11 | — | — | WO | claimed |
| US-9707219-B2 | Losmapimod for use in treating glomerular disease | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-07-18 | — | — | US | claimed |
| US-20100016377-A1 | Use of a p38 Kinase Inhibitor for Treating Psychiatric Disorders | GLAXOSMITHKLINE LLC | 2010-01-21 | — | — | US | claimed |
| US-20090074676-A1 | Inhibition of p38 MAPK For Treatment Of Obesity | SMITHKLINE BEECHAM CORPORATION | 2009-03-19 | — | — | US | claimed |
| EP-2029139-A1 | USE OF A P38 KINASE INHIBITOR FOR TREATING PSYCHIATRIC DISORDERS | SmithKline Beecham Corporation (US) | 2009-03-04 | — | — | EP | claimed |
| EP-1885181-A2 | INHIBITION OF P38 MARK FOR TREATMENT OF OBESITY | Smithkline Beecham Corporation (US) | 2008-02-13 | — | — | EP | claimed |
| WO-2007144390-A1 | USE OF A P38 KINASE INHIBITOR FOR TREATING PSYCHIATRIC DISORDERS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-12-21 | — | — | WO | claimed |
| EP-1474395-B1 | NICOTINAMIDE DERIVATES USEFUL AS P38 INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2007-10-17 | — | — | EP | claimed |
| WO-2006127678-A2 | INHIBITION OF P38 MARK FOR TREATMENT OF OBESITY | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-30 | — | — | WO | claimed |
| US-20060264479-A1 | Nicotinamide Derivatives Useful as p38 Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-11-23 | — | — | US | claimed |
| US-7125898-B2 | Nicotinamide derivatives useful as p38 inhibitors. | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-24 | — | — | US | claimed |
| US-20050176964-A1 | Nicotinamide derivatives useful as p38 inhibitors | GLAXOSMITHKLINE LLC | 2005-08-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12145981-B2 | Methods and compounds for the treatment or prevention of severe influenza | CXCL10, MAPK10, CCL11 | MAPK14 14/4885MAPK11 26/4885CYP2C9 4152/4885 |
| US-20060264479-A1 | Nicotinamide Derivatives Useful as p38 Inhibitors | MAPK1, MAPK7, MAPK6 | MAPK14 10/4885MAPK11 27/4885CYP2C9 2948/4885 |
| US-20100016377-A1 | Use of a p38 Kinase Inhibitor for Treating Psychiatric Disorders | MAPKAPK2, MAP4K2, MAPK1 | MAPK14 12/4885MAPK11 36/4885CYP2C9 4086/4885 |
| US-20180071376-A1 | TOLEROGENIC NANOPARTICLES FOR TREATING DIABETES MELLITUS | IAPP, NFATC1, CD4 | MAPK14 2820/4885MAPK11 2451/4885CYP2C9 4871/4885 |
| US-20220275062-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | CXCL10, MAPK10, CCL11 | MAPK14 14/4885MAPK11 26/4885CYP2C9 4152/4885 |
| US-20090074676-A1 | Inhibition of p38 MAPK For Treatment Of Obesity | MAPKAPK2, MAPK1, MAPK6 | MAPK14 16/4885MAPK11 13/4885CYP2C9 4792/4885 |
| US-20050176964-A1 | Nicotinamide derivatives useful as p38 inhibitors | MAPK1, MAPK7, MAPK6 | MAPK14 10/4885MAPK11 27/4885CYP2C9 2948/4885 |
| US-11339207-B2 | Methods and compounds for the treatment or prevention of severe influenza | CXCL10, MAPK10, MAPK1 | MAPK14 15/4885MAPK11 24/4885CYP2C9 4041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.